Founded in 1982, Orient EuroPharma Co., Ltd (OEP) was officially listed in the Gre-Tai Securities market in 2003, and consolidated net sales exceeded $4.5 billion in the 2013 financial year. Currently, OEP has more than 760 staffs worldwide, in which over 40% are overseas employees. OEP’s products include pharmaceuticals, cancer drugs, cosmeceutical, infant & adult nutrition and healthcare products. OEP also established a subsidiary company focused on developing and manufacturing new drugs. OEP is one of few pharmaceutical companies able to integrate pharmaceutical research & development, clinical trial, manufacture and marketing in Taiwan. In 2013, OEP was named 2nd Benchmark Pharmaceutical Company in 2013 The Leading Biomedical Businesses of Taiwan by the Institute for Biotechnology and Medicine Industry. CommonWealth Magazine also placed OEP among the top thousand large enterprises for three consecutive years.
OEP collaborated with multinational pharmaceutical companies to sell prescription drugs for five major treatments areas, including cardiovascular, cancer, central neuroscience system, respiratory, and hormones. For infant nutrition, OEP collaborated with New Zealand’s Dairy Goat Co-operatives (DGC) to mark and market a new goat milk powder brand, Karihome. Karihome has successfully entered the China and Southeast Asia market, and is one of the few Taiwanese companies able to manage an international brand. In addition, OEP is the first company to obtain the hyaluronic acid sale license in Taiwan. OEP launched its second hyaluronic acid product in 2014, while cooperating with European and Japanese companies to sell cosmeceutical products, such as the world-renowned skincare oil Bio-oil, and has won many major beauty awards and achieved great sales performance in Taiwan.
With the globalizing and growing market, OEP started to establish overseas subsidiaries in Singapore, Malaysia, Hong Kong and the Philippines since 1993. In 2006, OEP established the subsidiaries in Shanghai and Guangdong. In 2011, OEP expanded its market to Vietnam and planned to expand to Sri Lanka, Cambodia, Myanmar and India, strengthening OEP’s marketing and sales capability in the Asian Pacific region.
For sustainable development, OEP established a professional R&D group to focus on the research and development of new drugs. The subsidiary company OrientPHARMA Co., Ltd (OP) was founded in 2008 for developing and manufacturing new drugs. The OP plant is allocated in Huwei Park in Yunlin and has got the certifications of Taiwan PIC/S GMP, the “Accreditation Certification of Foreign Drug Manufacturer” from Japan MHLW, and US FDA international standards. Its progressive air-conditioning, water purification, air-compression and maintenance systems are capable of preventing plant and equipment cross contamination, and conform to international professional pharmaceutical standards for the next two decades. In 2012, OEP expanded its R&D capabilities in the cancer drug area, and signed an agreement with Japan NanoCarrier Co., Ltd. to jointly develop new cancer drugs. In 2013, OPNano Co., Ltd (ON) was established, and the new injection plant began construction in 2014.